Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1523 | Fecal Microbiota Therapy (FMT) Wiki | 1.00 |
| drug3502 | Saline Wiki | 0.32 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.
Description: Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.
Measure: A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization. Time: 15 daysDescription: Determine if degarelix + BSC as compared to placebo + BSC reduces time to clinical improvement as defined by a decline of 2 categories or more from the baseline on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients or hospital discharge whichever comes first.
Measure: Time to clinical improvement Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC reduces inpatient mortality.
Measure: Inpatient mortality Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of hospitalization.
Measure: Duration of hospitalization Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of intubation for mechanical ventilation.
Measure: Duration of intubation for mechanical ventilation. Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC reduces the time to normalization of temperature (T < 37.5 for 48 hours)
Measure: Time to normalization of temperature. Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + BSC as compared to placebo + BSC reduces the maximum severity of COVID-19 illness based on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients. Score range 1-7, higher scores equals worse outcome.
Measure: Maximum severity of COVID19 illness. Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)Description: Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.
Measure: A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization. Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports